A comprehensive view of Cancer. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Amgen's BLINCYTO for CD19-positive B-ALL in consolidation phase; 84.8% overall survival rate seen in trial.

Janssen-Cilag announces findings from RESONATE-2 study, confirming IMBRUVICA's sustained survival benefit for chronic lymphocytic leukaemia treatment over 10 years; final analysis shows significant progression-free and overall survival benefit.

Updated Phase 2 CAPTIVATE study shows fixed-duration IMBRUVICA plus venetoclax as first-line treatment for chronic lymphocytic leukaemia achieves sustained clinical benefit; 67% of patients were progression-free and alive at 5.5 years.

Janssen Pharmaceutical Companies spearheads industry evolution with CLL treatment innovations, AI in R&D, and diversity in clinical trials; Janssen increases life expectancy of CLL patients, uses AI i...

Bristol-Myers Squibb champions innovative treatments for HCM and melanoma; advances hematology and cell therapy, and strengthens community support

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count